- Home
- YOSH vs AIMD Comparison
YOSH vs AIMD Comparison
Compare YOSH & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- AIMD
- Stock Information
- Founded
- YOSH 2016
- AIMD 1984
- Country
- YOSH United States
- AIMD United States
- Employees
- YOSH N/A
- AIMD N/A
- Industry
- YOSH Restaurants
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- AIMD Health Care
- Exchange
- YOSH Nasdaq
- AIMD Nasdaq
- Market Cap
- YOSH 6.4M
- AIMD 5.2M
- IPO Year
- YOSH 2022
- AIMD N/A
- Fundamental
- Price
- YOSH $3.04
- AIMD $0.44
- Analyst Decision
- YOSH
- AIMD
- Analyst Count
- YOSH 0
- AIMD 0
- Target Price
- YOSH N/A
- AIMD N/A
- AVG Volume (30 Days)
- YOSH 54.0K
- AIMD 255.6K
- Earning Date
- YOSH 11-22-2024
- AIMD 11-06-2024
- Dividend Yield
- YOSH N/A
- AIMD N/A
- EPS Growth
- YOSH N/A
- AIMD N/A
- EPS
- YOSH N/A
- AIMD N/A
- Revenue
- YOSH $10,662,741.00
- AIMD $40,633.00
- Revenue This Year
- YOSH N/A
- AIMD N/A
- Revenue Next Year
- YOSH N/A
- AIMD N/A
- P/E Ratio
- YOSH N/A
- AIMD N/A
- Revenue Growth
- YOSH 18.50
- AIMD N/A
- 52 Week Low
- YOSH $2.73
- AIMD $0.40
- 52 Week High
- YOSH $13.86
- AIMD $4.29
- Technical
- Relative Strength Index (RSI)
- YOSH 29.54
- AIMD 38.69
- Support Level
- YOSH $2.73
- AIMD $0.44
- Resistance Level
- YOSH $5.25
- AIMD $0.52
- Average True Range (ATR)
- YOSH 0.91
- AIMD 0.05
- MACD
- YOSH -0.16
- AIMD -0.00
- Stochastic Oscillator
- YOSH 7.91
- AIMD 26.90
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.